The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Vadadustat in Patients with Anemia and Non–Dialysis-Dependent CKD
Open accessAbstract
BACKGROUND: Vadadustat is an oral hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitor, a class of drugs that stabilize HIF and stimulate erythropoietin and red-cell production. METHODS: In two phase 3, randomized, open-label, active-controlled, noninferiority trials, we compared vadadustat with the erythropoiesis-stimulating agent (ESA) darbepoetin alfa in patients with non-dialysis-dependent chronic kidney disease (NDD-CKD) not previously treated with an ESA who had a hemoglobin concentration of less than 10 g per deciliter and in patients with ESA-treated NDD-CKD and a hemoglobin concentration of 8 to 11 g per deciliter (in the United States) or 9 to 12 g per deciliter (in other countries). The primary safety end point, assessed in a time-to-event analysis, was the first major adverse cardiovascular event (MACE; a composite of death from any cause, nonfatal myocardial infarction, or nonfatal stroke), pooled across the two trials. Secondary safety end points included expanded MACE (MACE plus hospitalization for either heart failure or a thromboembolic event). The primary and key secondary efficacy end points in each trial were the mean change in hemoglobin concentration from baseline during two evaluation periods: weeks 24 through 36 and weeks 40 through 52. RESULTS: A total of 1751 patients with ESA-untreated NDD-CKD and 1725 with ESA-treated NDD-CKD underwent randomization in the two trials. In the pooled analysis, in which 1739 patients received vadadustat and 1732 received darbepoetin alfa, the hazard ratio for MACE was 1.17 (95% confidence interval [CI], 1.01 to 1.36), which did not meet the prespecified noninferiority margin of 1.25. The mean between-group differences in the change in the hemoglobin concentration at weeks 24 through 36 were 0.05 g per deciliter (95% CI, -0.04 to 0.15) in the trial involving ESA-untreated patients and -0.01 g per deciliter (95% CI, -0.09 to 0.07) in the trial involving ESA-treated patients, which met the prespecified noninferiority margin of -0.75 g per deciliter. CONCLUSIONS: TECT ClinicalTrials.gov numbers, NCT02648347 and NCT02680574.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Equation to Estimate Glomerular Filtration Rate
Levey, A. S., Stevens, L. A., Schmid, C. H., Zhang, Y. (., Castro, A. F., Feldman, H. I., Kusek, J. W., Eggers, P., Van Lente, F., Greene, T., et al. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-9-200905050-00006 · Cited by 25,603
KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease
Stevens, P. E., Ahmed, S. B., Carrero, J. J., Foster, B., Francis, A., Hall, R. K., Herrington, W. G., Hill, G., Inker, L. A., Kazancıoğlu, R., et al. (2024) · Kidney International · doi:10.1016/j.kint.2023.10.018 · Cited by 8,530
Hypoxia-inducible factors in physiology and medicine
Semenza, G. L. (2012) · Cell · doi:10.1016/j.cell.2012.01.021 · Cited by 3,645
Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway.
Kaelin, W. G., & Ratcliffe, P. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.04.009 · Cited by 3,251
(2013) · Kidney International Supplements · doi:10.1038/kisup.2012.73 · Cited by 3,206
Correction of anemia with epoetin alfa in chronic kidney disease
Singh, A. K., Szczech, L., Tang, K. L., Barnhart, H., Sapp, S., Wolfson, M., & Reddan, D. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa065485 · Cited by 2,762
Normalization of Hemoglobin Level in Patients with Chronic Kidney Disease and Anemia
Drüeke, T. B., Locatelli, F., Clyne, N., Eckardt, K.-U., Macdougall, I. C., Tsakiris, D., Burger, H.-U., & Scherhag, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062276 · Cited by 2,104
Self-citationA trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Pfeffer, M. A., Burdmann, E. A., Chen, C.-Y., Cooper, M. E., de Zeeuw, D., Eckardt, K.-U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0907845 · Cited by 2,096
Self-citationRegulation of erythropoiesis by hypoxia-inducible factors
Haase, V. H. (2013) · Blood Reviews · doi:10.1016/j.blre.2012.12.003 · Cited by 787
Prevalence of Anemia in Chronic Kidney Disease in the United States
Stauffer, M. E., & Fan, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084943 · Cited by 666
Hsu, C.-Y., McCulloch, C. E., & Curhan, G. C. (2002) · Journal of the American Society of Nephrology · doi:10.1681/asn.v132504 · Cited by 453
Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
Bernhardt, W. M., Wiesener, M. S., Scigalla, P., Chou, J., Schmieder, R. E., Günzler, V., & Eckardt, K.-U. (2010) · Journal of the American Society of Nephrology · doi:10.1681/asn.2010010116 · Cited by 340
Self-citationPergola, P. E., Spinowitz, B. S., Hartman, C. S., Maroni, B. J., & Haase, V. H. (2016) · Kidney International · doi:10.1016/j.kint.2016.07.019 · Cited by 237
Self-citationSafety and Efficacy of Vadadustat for Anemia in Patients Undergoing Dialysis
Eckardt, K.-U., Agarwal, R., Aswad, A., Awad, A., Block, G. A., Bacci, M. R., Farag, Y. M. K., Fishbane, S., Hubert, H., Jardine, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2025956 · Cited by 211
Self-citationMartin, E. R., Smith, M. T., Maroni, B. J., Zuraw, Q., & deGoma, E. M. (2017) · American Journal of Nephrology · doi:10.1159/000464476 · Cited by 129
Self-citationPeginesatide for Anemia in Patients with Chronic Kidney Disease Not Receiving Dialysis
Macdougall, I. C., Provenzano, R., Sharma, A. K., Spinowitz, B., Schmidt, R. J., Pérgola, P. E., Zabaneh, R. I., Tong-Starksen, S., Mayo, M. R., Tang, H., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1203166 · Cited by 118
Self-citationPeginesatide in Patients with Anemia Undergoing Hemodialysis
Fishbane, S. N., Schiller, B. M., Locatelli, F., Covic, A. C., Provenzano, R., Więcek, A., Levin, N. W., Kaplan, M., Macdougall, I. C., Francisco, C. A., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1203165 · Cited by 111
Nangaku, M., Farag, Y. M. K., deGoma, E. M., Luo, W. F., Vargo, D. L., & Khawaja, Z. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa060 · Cited by 48
Self-citationChertow, G. M., Pérgola, P. E., Agarwal, R., Block, G. A., Farag, Y. M. K., Jardine, A. G., Koury, M. J., Luo, W. F., Khawaja, Z., Lewis, E. F., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.10.068 · Cited by 10
Self-citation
Cited by
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Self-citationHypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
“25 but achieved the prespecified non-inferiority for hematologic efficacy.(508) Roxadustat has been authorized for China in dialysis-dependent CKD anemia patients’ treatment.”
BackgroundZoccali, C., Mallamaci, F., Adamczak, M., de Oliveira, R. B., Massy, Z. A., Sarafidis, P., Agarwal, R., Mark, P. B., Kotanko, P., Ferro, C. J., et al. (2023) · Cardiovascular Research · doi:10.1093/cvr/cvad083 · Cited by 363
Self-citationGlobal, Regional, and National Burden of Diabetes-Related Chronic Kidney Disease From 1990 to 2019
Deng, Y., Li, N., Wu, Y., Wang, M., Yang, S., Zheng, Y., Deng, X., Xiang, D., Zhu, Y., Xu, P., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.672350 · Cited by 319
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
Yuan, X., Ruan, W., Bobrow, B., Carmeliet, P., & Eltzschig, H. K. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00848-6 · Cited by 245
Metadata
- Authors
- Chertow, G. M., Pergola, P. E., Farag, Y. M. K., Agarwal, R., Arnold, S., Bako, G., Block, G. A., Burke, S., Castillo, F. P., Jardine, A. G., Khawaja, Z., Koury, M. J., Lewis, E. F., Lin, T., Luo, W., Maroni, B. J., Matsushita, K., McCullough, P. A., Parfrey, P. S., Roy-Chaudhury, P., Sarnak, M. J., Sharma, A., Spinowitz, B., Tseng, C., Tumlin, J., Vargo, D. L., Walters, K. A., Winkelmayer, W. C., Wittes, J., & Eckardt, K.-U.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-29
- Volume
- 384
- Issue
- 17
- Pages
- 1589-1600
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3159725307
- Cited by
- 254
- References
- 19
- FWCI
- 24.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.